Abstract LB-202: Phase 1 dose escalation trial of the novel vascular disrupting agent NPI-2358

2008 
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    1
    Citations
    NaN
    KQI
    []